Personalis, Inc. (NASDAQ:PSNL – Free Report) – Research analysts at HC Wainwright decreased their FY2024 EPS estimates for Personalis in a research note issued on Monday, January 27th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($1.36) for the year, down from their previous estimate of ($1.29). HC Wainwright currently has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Personalis’ current full-year earnings is ($1.37) per share. HC Wainwright also issued estimates for Personalis’ Q4 2024 earnings at ($0.21) EPS, Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.22) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.91) EPS, FY2026 earnings at ($0.71) EPS, FY2027 earnings at ($0.39) EPS and FY2028 earnings at ($0.05) EPS.
Personalis (NASDAQ:PSNL – Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.31). Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. The business had revenue of $25.71 million for the quarter, compared to the consensus estimate of $20.67 million. During the same period in the previous year, the firm earned ($0.51) EPS.
Get Our Latest Analysis on Personalis
Personalis Stock Performance
Shares of PSNL opened at $5.01 on Wednesday. The firm has a market capitalization of $353.95 million, a price-to-earnings ratio of -2.98 and a beta of 1.75. The stock’s fifty day moving average is $4.93 and its 200-day moving average is $4.75. Personalis has a one year low of $1.12 and a one year high of $7.20.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the company. nVerses Capital LLC acquired a new stake in Personalis in the 3rd quarter valued at about $40,000. SG Americas Securities LLC bought a new stake in shares of Personalis in the 4th quarter worth approximately $63,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Personalis in the 4th quarter worth approximately $87,000. IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its stake in Personalis by 42.5% during the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 15,103 shares of the company’s stock valued at $81,000 after purchasing an additional 4,504 shares during the last quarter. Finally, International Assets Investment Management LLC boosted its holdings in Personalis by 438.0% during the third quarter. International Assets Investment Management LLC now owns 20,982 shares of the company’s stock worth $113,000 after buying an additional 17,082 shares in the last quarter. 61.91% of the stock is owned by institutional investors and hedge funds.
Personalis Company Profile
Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.
Further Reading
- Five stocks we like better than Personalis
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- 3 Healthcare Dividend Stocks to Buy
- 3 Steel Stocks Soaring After Tariff Announcements
- The 3 Best Fintech Stocks to Buy Now
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.